Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 5/20 | 0.50 |
| ▸ | ELANE | P08246 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CTSV | O60911 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.50 |
| ▸ | LONP1 | P36776 | 3/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.41 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.41 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.41 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.41 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12296170 | 1.00 | ABCG2 (0.51) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL2409932 | 0.99 | ABCG2 (0.52) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL15247708 | 0.99 | ABCG2 (0.52) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL2409946 | 0.99 | ABCG2 (0.52) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL3198890 | 0.99 | ABCG2 (0.52) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL2409941 | 0.99 | ABCG2 (0.52) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL3223467 | 0.91 | ABCG2 (0.51) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL464151 | 0.89 | ABCG2 (0.53) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL1013602 | 0.88 | ABCG2 (0.54) | ABCG2CTSBELANECTSLCTSV | |
| SCHEMBL12011280 | 0.88 | ABCG2 (0.54) | ABCG2CTSBELANECTSLCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| EP-2371839-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2368877-A1 | Chiral intermediates for the preparation of peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368901-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-28 | — | — | EP | disclosed |
| US-7820671-B2 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
| EP-1849797-A2 | Peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | ABCG2 2283/4885CTSB 39/4885ELANE 600/4885 |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | ABCG2 2283/4885CTSB 39/4885ELANE 600/4885 |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | ABCG2 2283/4885CTSB 39/4885ELANE 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.